Global Peptide Cancer Vaccine Market Insights and Forecast to 2028

Global Peptide Cancer Vaccine Market Insights and Forecast to 2028

Table of Contents
1 Study Coverage
1.1 Peptide Cancer Vaccine Product Introduction
1.2 Market by Pipeline
1.2.1 Global Peptide Cancer Vaccine Market Size Growth Rate by Pipeline, 2017 VS 2021 VS 2028
1.2.2 ITK-1
1.2.3 GRN-1201
1.2.4 TPIV200
1.2.5 TPIV110
1.2.6 UV1
1.2.7 Galinpepimut-S
1.2.8 TARP 27-35
1.2.9 HER-Vaxx
1.2.10 Vx-001
1.2.11 Others
1.3 Market by Application
1.3.1 Global Peptide Cancer Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Breast Cancer
1.3.3 Lung Cancer
1.3.4 Melanoma
1.3.5 Prostate Cancer
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Peptide Cancer Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Peptide Cancer Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Peptide Cancer Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Peptide Cancer Vaccine Sales by Region
2.4.1 Global Peptide Cancer Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Peptide Cancer Vaccine by Region (2023-2028)
2.5 Global Peptide Cancer Vaccine Revenue by Region
2.5.1 Global Peptide Cancer Vaccine Revenue by Region (2017-2022)
2.5.2 Global Peptide Cancer Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Peptide Cancer Vaccine Sales by Manufacturers
3.1.1 Global Top Peptide Cancer Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Peptide Cancer Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Peptide Cancer Vaccine in 2021
3.2 Global Peptide Cancer Vaccine Revenue by Manufacturers
3.2.1 Global Peptide Cancer Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Peptide Cancer Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Peptide Cancer Vaccine Revenue in 2021
3.3 Global Peptide Cancer Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Peptide Cancer Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Pipeline
4.1 Global Peptide Cancer Vaccine Sales by Pipeline
4.1.1 Global Peptide Cancer Vaccine Historical Sales by Pipeline (2017-2022)
4.1.2 Global Peptide Cancer Vaccine Forecasted Sales by Pipeline (2023-2028)
4.1.3 Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2028)
4.2 Global Peptide Cancer Vaccine Revenue by Pipeline
4.2.1 Global Peptide Cancer Vaccine Historical Revenue by Pipeline (2017-2022)
4.2.2 Global Peptide Cancer Vaccine Forecasted Revenue by Pipeline (2023-2028)
4.2.3 Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2017-2028)
4.3 Global Peptide Cancer Vaccine Price by Pipeline
4.3.1 Global Peptide Cancer Vaccine Price by Pipeline (2017-2022)
4.3.2 Global Peptide Cancer Vaccine Price Forecast by Pipeline (2023-2028)
5 Market Size by Application
5.1 Global Peptide Cancer Vaccine Sales by Application
5.1.1 Global Peptide Cancer Vaccine Historical Sales by Application (2017-2022)
5.1.2 Global Peptide Cancer Vaccine Forecasted Sales by Application (2023-2028)
5.1.3 Global Peptide Cancer Vaccine Sales Market Share by Application (2017-2028)
5.2 Global Peptide Cancer Vaccine Revenue by Application
5.2.1 Global Peptide Cancer Vaccine Historical Revenue by Application (2017-2022)
5.2.2 Global Peptide Cancer Vaccine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Peptide Cancer Vaccine Revenue Market Share by Application (2017-2028)
5.3 Global Peptide Cancer Vaccine Price by Application
5.3.1 Global Peptide Cancer Vaccine Price by Application (2017-2022)
5.3.2 Global Peptide Cancer Vaccine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Peptide Cancer Vaccine Market Size by Pipeline
6.1.1 North America Peptide Cancer Vaccine Sales by Pipeline (2017-2028)
6.1.2 North America Peptide Cancer Vaccine Revenue by Pipeline (2017-2028)
6.2 North America Peptide Cancer Vaccine Market Size by Application
6.2.1 North America Peptide Cancer Vaccine Sales by Application (2017-2028)
6.2.2 North America Peptide Cancer Vaccine Revenue by Application (2017-2028)
6.3 North America Peptide Cancer Vaccine Market Size by Country
6.3.1 North America Peptide Cancer Vaccine Sales by Country (2017-2028)
6.3.2 North America Peptide Cancer Vaccine Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Peptide Cancer Vaccine Market Size by Pipeline
7.1.1 Europe Peptide Cancer Vaccine Sales by Pipeline (2017-2028)
7.1.2 Europe Peptide Cancer Vaccine Revenue by Pipeline (2017-2028)
7.2 Europe Peptide Cancer Vaccine Market Size by Application
7.2.1 Europe Peptide Cancer Vaccine Sales by Application (2017-2028)
7.2.2 Europe Peptide Cancer Vaccine Revenue by Application (2017-2028)
7.3 Europe Peptide Cancer Vaccine Market Size by Country
7.3.1 Europe Peptide Cancer Vaccine Sales by Country (2017-2028)
7.3.2 Europe Peptide Cancer Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Peptide Cancer Vaccine Market Size by Pipeline
8.1.1 Asia Pacific Peptide Cancer Vaccine Sales by Pipeline (2017-2028)
8.1.2 Asia Pacific Peptide Cancer Vaccine Revenue by Pipeline (2017-2028)
8.2 Asia Pacific Peptide Cancer Vaccine Market Size by Application
8.2.1 Asia Pacific Peptide Cancer Vaccine Sales by Application (2017-2028)
8.2.2 Asia Pacific Peptide Cancer Vaccine Revenue by Application (2017-2028)
8.3 Asia Pacific Peptide Cancer Vaccine Market Size by Region
8.3.1 Asia Pacific Peptide Cancer Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Peptide Cancer Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Peptide Cancer Vaccine Market Size by Pipeline
9.1.1 Latin America Peptide Cancer Vaccine Sales by Pipeline (2017-2028)
9.1.2 Latin America Peptide Cancer Vaccine Revenue by Pipeline (2017-2028)
9.2 Latin America Peptide Cancer Vaccine Market Size by Application
9.2.1 Latin America Peptide Cancer Vaccine Sales by Application (2017-2028)
9.2.2 Latin America Peptide Cancer Vaccine Revenue by Application (2017-2028)
9.3 Latin America Peptide Cancer Vaccine Market Size by Country
9.3.1 Latin America Peptide Cancer Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Peptide Cancer Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Peptide Cancer Vaccine Market Size by Pipeline
10.1.1 Middle East and Africa Peptide Cancer Vaccine Sales by Pipeline (2017-2028)
10.1.2 Middle East and Africa Peptide Cancer Vaccine Revenue by Pipeline (2017-2028)
10.2 Middle East and Africa Peptide Cancer Vaccine Market Size by Application
10.2.1 Middle East and Africa Peptide Cancer Vaccine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Peptide Cancer Vaccine Revenue by Application (2017-2028)
10.3 Middle East and Africa Peptide Cancer Vaccine Market Size by Country
10.3.1 Middle East and Africa Peptide Cancer Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Boston Biomedical
11.1.1 Boston Biomedical Corporation Information
11.1.2 Boston Biomedical Overview
11.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Boston Biomedical Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Boston Biomedical Recent Developments
11.2 Ultimovacs
11.2.1 Ultimovacs Corporation Information
11.2.2 Ultimovacs Overview
11.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Ultimovacs Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Ultimovacs Recent Developments
11.3 BrightPath Biotherapeutics
11.3.1 BrightPath Biotherapeutics Corporation Information
11.3.2 BrightPath Biotherapeutics Overview
11.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 BrightPath Biotherapeutics Recent Developments
11.4 TapImmune
11.4.1 TapImmune Corporation Information
11.4.2 TapImmune Overview
11.4.3 TapImmune Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 TapImmune Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 TapImmune Recent Developments
11.5 Immatics
11.5.1 Immatics Corporation Information
11.5.2 Immatics Overview
11.5.3 Immatics Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Immatics Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Immatics Recent Developments
11.6 Sellas
11.6.1 Sellas Corporation Information
11.6.2 Sellas Overview
11.6.3 Sellas Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Sellas Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Sellas Recent Developments
11.7 Imugene
11.7.1 Imugene Corporation Information
11.7.2 Imugene Overview
11.7.3 Imugene Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Imugene Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Imugene Recent Developments
11.8 VAXON Biotech
11.8.1 VAXON Biotech Corporation Information
11.8.2 VAXON Biotech Overview
11.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 VAXON Biotech Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 VAXON Biotech Recent Developments
11.9 Generex Biotechnology
11.9.1 Generex Biotechnology Corporation Information
11.9.2 Generex Biotechnology Overview
11.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Generex Biotechnology Recent Developments
11.10 ISA Pharmaceuticals
11.10.1 ISA Pharmaceuticals Corporation Information
11.10.2 ISA Pharmaceuticals Overview
11.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 ISA Pharmaceuticals Recent Developments
11.11 OncoTherapy Science
11.11.1 OncoTherapy Science Corporation Information
11.11.2 OncoTherapy Science Overview
11.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 OncoTherapy Science Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Peptide Cancer Vaccine Industry Chain Analysis
12.2 Peptide Cancer Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Peptide Cancer Vaccine Production Mode & Process
12.4 Peptide Cancer Vaccine Sales and Marketing
12.4.1 Peptide Cancer Vaccine Sales Channels
12.4.2 Peptide Cancer Vaccine Distributors
12.5 Peptide Cancer Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Peptide Cancer Vaccine Industry Trends
13.2 Peptide Cancer Vaccine Market Drivers
13.3 Peptide Cancer Vaccine Market Challenges
13.4 Peptide Cancer Vaccine Market Restraints
14 Key Findings in The Global Peptide Cancer Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Peptide Cancer Vaccine Market Size Growth Rate by Pipeline, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of ITK-1
Table 3. Major Manufacturers of GRN-1201
Table 4. Major Manufacturers of TPIV200
Table 5. Major Manufacturers of TPIV110
Table 6. Major Manufacturers of UV1
Table 7. Major Manufacturers of Galinpepimut-S
Table 8. Major Manufacturers of TARP 27-35
Table 9. Major Manufacturers of HER-Vaxx
Table 10. Major Manufacturers of Vx-001
Table 11. Major Manufacturers of Others
Table 12. Global Peptide Cancer Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 13. Global Peptide Cancer Vaccine Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 14. Global Peptide Cancer Vaccine Sales by Region (2017-2022) & (K Doses)
Table 15. Global Peptide Cancer Vaccine Sales Market Share by Region (2017-2022)
Table 16. Global Peptide Cancer Vaccine Sales by Region (2023-2028) & (K Doses)
Table 17. Global Peptide Cancer Vaccine Sales Market Share by Region (2023-2028)
Table 18. Global Peptide Cancer Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 19. Global Peptide Cancer Vaccine Revenue Market Share by Region (2017-2022)
Table 20. Global Peptide Cancer Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 21. Global Peptide Cancer Vaccine Revenue Market Share by Region (2023-2028)
Table 22. Global Peptide Cancer Vaccine Sales by Manufacturers (2017-2022) & (K Doses)
Table 23. Global Peptide Cancer Vaccine Sales Share by Manufacturers (2017-2022)
Table 24. Global Peptide Cancer Vaccine Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 25. Global Peptide Cancer Vaccine Revenue Share by Manufacturers (2017-2022)
Table 26. Peptide Cancer Vaccine Price by Manufacturers (2017-2022) &(USD/Dose)
Table 27. Global Peptide Cancer Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Peptide Cancer Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Cancer Vaccine as of 2021)
Table 29. Peptide Cancer Vaccine Manufacturing Base Distribution and Headquarters
Table 30. Manufacturers Peptide Cancer Vaccine Product Offered
Table 31. Date of Manufacturers Enter into Peptide Cancer Vaccine Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
Table 34. Global Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
Table 35. Global Peptide Cancer Vaccine Sales Share by Pipeline (2017-2022)
Table 36. Global Peptide Cancer Vaccine Sales Share by Pipeline (2023-2028)
Table 37. Global Peptide Cancer Vaccine Revenue by Pipeline (2017-2022) & (US$ Million)
Table 38. Global Peptide Cancer Vaccine Revenue by Pipeline (2023-2028) & (US$ Million)
Table 39. Global Peptide Cancer Vaccine Revenue Share by Pipeline (2017-2022)
Table 40. Global Peptide Cancer Vaccine Revenue Share by Pipeline (2023-2028)
Table 41. Peptide Cancer Vaccine Price by Pipeline (2017-2022) & (USD/Dose)
Table 42. Global Peptide Cancer Vaccine Price Forecast by Pipeline (2023-2028) & (USD/Dose)
Table 43. Global Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 44. Global Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 45. Global Peptide Cancer Vaccine Sales Share by Application (2017-2022)
Table 46. Global Peptide Cancer Vaccine Sales Share by Application (2023-2028)
Table 47. Global Peptide Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 48. Global Peptide Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 49. Global Peptide Cancer Vaccine Revenue Share by Application (2017-2022)
Table 50. Global Peptide Cancer Vaccine Revenue Share by Application (2023-2028)
Table 51. Peptide Cancer Vaccine Price by Application (2017-2022) & (USD/Dose)
Table 52. Global Peptide Cancer Vaccine Price Forecast by Application (2023-2028) & (USD/Dose)
Table 53. North America Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
Table 54. North America Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
Table 55. North America Peptide Cancer Vaccine Revenue by Pipeline (2017-2022) & (US$ Million)
Table 56. North America Peptide Cancer Vaccine Revenue by Pipeline (2023-2028) & (US$ Million)
Table 57. North America Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 58. North America Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 59. North America Peptide Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 60. North America Peptide Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 61. North America Peptide Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
Table 62. North America Peptide Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
Table 63. North America Peptide Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 64. North America Peptide Cancer Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 65. Europe Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
Table 66. Europe Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
Table 67. Europe Peptide Cancer Vaccine Revenue by Pipeline (2017-2022) & (US$ Million)
Table 68. Europe Peptide Cancer Vaccine Revenue by Pipeline (2023-2028) & (US$ Million)
Table 69. Europe Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 70. Europe Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 71. Europe Peptide Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 72. Europe Peptide Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 73. Europe Peptide Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
Table 74. Europe Peptide Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
Table 75. Europe Peptide Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 76. Europe Peptide Cancer Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 77. Asia Pacific Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
Table 78. Asia Pacific Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
Table 79. Asia Pacific Peptide Cancer Vaccine Revenue by Pipeline (2017-2022) & (US$ Million)
Table 80. Asia Pacific Peptide Cancer Vaccine Revenue by Pipeline (2023-2028) & (US$ Million)
Table 81. Asia Pacific Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 82. Asia Pacific Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 83. Asia Pacific Peptide Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 84. Asia Pacific Peptide Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 85. Asia Pacific Peptide Cancer Vaccine Sales by Region (2017-2022) & (K Doses)
Table 86. Asia Pacific Peptide Cancer Vaccine Sales by Region (2023-2028) & (K Doses)
Table 87. Asia Pacific Peptide Cancer Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 88. Asia Pacific Peptide Cancer Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 89. Latin America Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
Table 90. Latin America Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
Table 91. Latin America Peptide Cancer Vaccine Revenue by Pipeline (2017-2022) & (US$ Million)
Table 92. Latin America Peptide Cancer Vaccine Revenue by Pipeline (2023-2028) & (US$ Million)
Table 93. Latin America Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 94. Latin America Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 95. Latin America Peptide Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 96. Latin America Peptide Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 97. Latin America Peptide Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
Table 98. Latin America Peptide Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
Table 99. Latin America Peptide Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 100. Latin America Peptide Cancer Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Peptide Cancer Vaccine Sales by Pipeline (2017-2022) & (K Doses)
Table 102. Middle East and Africa Peptide Cancer Vaccine Sales by Pipeline (2023-2028) & (K Doses)
Table 103. Middle East and Africa Peptide Cancer Vaccine Revenue by Pipeline (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Peptide Cancer Vaccine Revenue by Pipeline (2023-2028) & (US$ Million)
Table 105. Middle East and Africa Peptide Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 106. Middle East and Africa Peptide Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 107. Middle East and Africa Peptide Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 108. Middle East and Africa Peptide Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 109. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
Table 110. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
Table 111. Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 112. Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 113. Boston Biomedical Corporation Information
Table 114. Boston Biomedical Description and Major Businesses
Table 115. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 116. Boston Biomedical Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Boston Biomedical Recent Developments
Table 118. Ultimovacs Corporation Information
Table 119. Ultimovacs Description and Major Businesses
Table 120. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 121. Ultimovacs Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Ultimovacs Recent Developments
Table 123. BrightPath Biotherapeutics Corporation Information
Table 124. BrightPath Biotherapeutics Description and Major Businesses
Table 125. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 126. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. BrightPath Biotherapeutics Recent Developments
Table 128. TapImmune Corporation Information
Table 129. TapImmune Description and Major Businesses
Table 130. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 131. TapImmune Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. TapImmune Recent Developments
Table 133. Immatics Corporation Information
Table 134. Immatics Description and Major Businesses
Table 135. Immatics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 136. Immatics Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Immatics Recent Developments
Table 138. Sellas Corporation Information
Table 139. Sellas Description and Major Businesses
Table 140. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 141. Sellas Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Sellas Recent Developments
Table 143. Imugene Corporation Information
Table 144. Imugene Description and Major Businesses
Table 145. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 146. Imugene Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. Imugene Recent Developments
Table 148. VAXON Biotech Corporation Information
Table 149. VAXON Biotech Description and Major Businesses
Table 150. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 151. VAXON Biotech Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 152. VAXON Biotech Recent Developments
Table 153. Generex Biotechnology Corporation Information
Table 154. Generex Biotechnology Description and Major Businesses
Table 155. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 156. Generex Biotechnology Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 157. Generex Biotechnology Recent Developments
Table 158. ISA Pharmaceuticals Corporation Information
Table 159. ISA Pharmaceuticals Description and Major Businesses
Table 160. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 161. ISA Pharmaceuticals Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 162. ISA Pharmaceuticals Recent Developments
Table 163. OncoTherapy Science Corporation Information
Table 164. OncoTherapy Science Description and Major Businesses
Table 165. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 166. OncoTherapy Science Peptide Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 167. OncoTherapy Science Recent Developments
Table 168. Key Raw Materials Lists
Table 169. Raw Materials Key Suppliers Lists
Table 170. Peptide Cancer Vaccine Distributors List
Table 171. Peptide Cancer Vaccine Customers List
Table 172. Peptide Cancer Vaccine Market Trends
Table 173. Peptide Cancer Vaccine Market Drivers
Table 174. Peptide Cancer Vaccine Market Challenges
Table 175. Peptide Cancer Vaccine Market Restraints
Table 176. Research Programs/Design for This Report
Table 177. Key Data Information from Secondary Sources
Table 178. Key Data Information from Primary Sources
List of Figures
Figure 1. Peptide Cancer Vaccine Product Picture
Figure 3. Global Peptide Cancer Vaccine Market Share by Pipeline in 2021 & 2028
Figure 3. ITK-1 Product Picture
Figure 4. GRN-1201 Product Picture
Figure 5. TPIV200 Product Picture
Figure 6. TPIV110 Product Picture
Figure 7. UV1 Product Picture
Figure 8. Galinpepimut-S Product Picture
Figure 9. TARP 27-35 Product Picture
Figure 10. HER-Vaxx Product Picture
Figure 11. Vx-001 Product Picture
Figure 12. Others Product Picture
Figure 13. Global Peptide Cancer Vaccine Market Share by Application in 2021 & 2028
Figure 14. Breast Cancer
Figure 15. Lung Cancer
Figure 16. Melanoma
Figure 17. Prostate Cancer
Figure 18. Others
Figure 19. Peptide Cancer Vaccine Report Years Considered
Figure 20. Global Peptide Cancer Vaccine Sales 2017-2028 (K Doses)
Figure 21. Global Peptide Cancer Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 22. Global Peptide Cancer Vaccine Revenue 2017-2028 (US$ Million)
Figure 23. Global Peptide Cancer Vaccine Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 24. Global Peptide Cancer Vaccine Sales Market Share by Region (2017-2022)
Figure 25. Global Peptide Cancer Vaccine Sales Market Share by Region (2023-2028)
Figure 26. North America Peptide Cancer Vaccine Sales YoY (2017-2028) & (K Doses)
Figure 27. North America Peptide Cancer Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 28. Europe Peptide Cancer Vaccine Sales YoY (2017-2028) & (K Doses)
Figure 29. Europe Peptide Cancer Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 30. Asia-Pacific Peptide Cancer Vaccine Sales YoY (2017-2028) & (K Doses)
Figure 31. Asia-Pacific Peptide Cancer Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 32. Latin America Peptide Cancer Vaccine Sales YoY (2017-2028) & (K Doses)
Figure 33. Latin America Peptide Cancer Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 34. Middle East & Africa Peptide Cancer Vaccine Sales YoY (2017-2028) & (K Doses)
Figure 35. Middle East & Africa Peptide Cancer Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 36. The Peptide Cancer Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 37. The Top 5 and 10 Largest Manufacturers of Peptide Cancer Vaccine in the World: Market Share by Peptide Cancer Vaccine Revenue in 2021
Figure 38. Global Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 39. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2028)
Figure 40. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2017-2028)
Figure 41. Global Peptide Cancer Vaccine Sales Market Share by Application (2017-2028)
Figure 42. Global Peptide Cancer Vaccine Revenue Market Share by Application (2017-2028)
Figure 43. North America Peptide Cancer Vaccine Sales Market Share by Pipeline (2017-2028)
Figure 44. North America Peptide Cancer Vaccine Revenue Market Share by Pipeline (2017-2028)
Figure 45. North America Peptide

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global BCG Vaccine Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 96

According to our LPI (LP Information) latest study, the global BCG Vaccine market size was valued at US$ 365.6 million in 2023. With growing demand in downstream market, the BCG Vaccine is forecast to a readjusted size of US$ 542.8 million by 2030 with a CAGR of 5.8% during review period. The research report highlights the growth potential of the global BCG Vaccine market. BCG Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing cost......

Global Peptide Cancer Vaccine Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 115

According to our LPI (LP Information) latest study, the global Peptide Cancer Vaccine market size was valued at US$ 535 million in 2023. With growing demand in downstream market, the Peptide Cancer Vaccine is forecast to a readjusted size of US$ 1978.2 million by 2030 with a CAGR of 20.5% during review period. The research report highlights the growth potential of the global Peptide Cancer Vaccine market. Peptide Cancer Vaccine are expected to show stable growth in the future market. How......

Global Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 101

Market Overview of Global Cancer Vaccine market: According to our latest research, the global Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Cancer Vaccine market was estimated at USD 7198.2 million, and it's anticipated to reach USD 33936.62 million in 2028, with a CAGR of 29.49% during the forecast years. A cancer vaccine is a type of immunotherapy that boost the body's natural defenses by stimulating the immune system to recognize and cur......

Global Lung Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 12-Dec-2023        Price: US 3380 Onwards        Pages: 102

Market Overview of Global Lung Cancer Vaccines market: According to our latest research, the global Lung Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Lung Cancer Vaccines market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Lung Cancer Vaccines,A cancer vaccine for lung cance This report covers a research time span from 2018 to 2028, and ......

Global Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 07-Dec-2023        Price: US 3380 Onwards        Pages: 105

Market Overview of Global Cancer Vaccines market: According to our latest research, the global Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Cancer Vaccines market was estimated at USD 5773.14 million, and it's anticipated to reach USD 15406.41 million in 2028, with a CAGR of 17.77% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Vacci......

Global Dendritic Cell Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 110

Market Overview of Global Dendritic Cell Cancer Vaccine market: According to our latest research, the global Dendritic Cell Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Dendritic Cell Cancer Vaccine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Dendritic cells (DC) are one of the major antigen presenting cells found in lymphoid organs. The main fu......

Global BCG Vaccine Market Research Report 2023, Forecast to 2028

Published: 14-Nov-2023        Price: US 2680 Onwards        Pages: 135

BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......

Global BCG Vaccine Professional Survey Report 2023, Forecast to 2028

Published: 14-Nov-2023        Price: US 3280 Onwards        Pages: 105

BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......

Infectious Vaccine Collaboration and Licensing Deals 2016-2023

Published: 01-Nov-2023        Price: US 3995 Onwards        Pages: 300

Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious vaccine deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of infectious vaccine deals from 2016 to 2023. The report provides a detailed understanding and analysis of how and why companies enter infectious vaccine deals. These deals tend to be multicomponent, starting with......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs